Evolving Testing and Treatment Strategies in Metastatic Colorectal Cancer
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Biomarker Testing in Metastatic Colorectal Cancer By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.
EP. 2: ctDNA and MRD Testing in Nonmetastatic Colorectal Cancer By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.
EP. 3: Colorectal Cancer: Evolving Role of ctDNA Testing in Practice By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.
EP. 4: Treatment Options for BRAF V600E–Mutant Metastatic Colorectal Cancer By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.
EP. 5: BRAF V600E–Mutant Metastatic Colorectal Cancer: BREAKWATER Study By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.
EP. 6: Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.
EP. 7: Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal Cancer By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.
EP. 8: Assessing HER2 Expression in Metastatic Colorectal Cancer By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.
EP. 9: HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.
EP. 10: HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.
EP. 11: Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care By John Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center, Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Aparna R. Parikh, MD, Stacey A. Cohen, MD Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
